Navigation Links
Discovery of variations in resistance to sulfadoxine across Africa
Date:4/14/2009

Researchers have discovered that malaria parasites in east and west Africa carry different resistance mutations, which suggests that the effectiveness of sulfadoxine as an antimalarial drug may vary across Africa.

The findings have implications for the manner in which malaria control campaigns are carried out, and suggest that coordinating efforts between parts of Africa that share similar patterns of resistance is likely to be more effective than working in isolation in each country.

Plasmodium falciparum (P. falciparum) a mosquito-borne parasite that causes malaria, kills nearly one million people a year, mostly in sub-Saharan Africa. Until recently, treatment in Africa relied on chloroquine and sulfadoxine-pyrimethamine. Unfortunately, parasites have developed resistance to both these drugs by acquiring 'resistance mutations', genetic changes that prevent the drugs from killing them.

Scientists have discovered that the mutations that caused resistance to chloroquine and pyrimethamine originated in Asia and spread into Africa in the late 1970s and early 1980s respectively. These mutations are now common across Africa and it is no longer possible to determine how they spread across the continent. However, the mutations that cause resistance to sulfadoxine only began to emerge in the mid-1990s, and have not yet spread evenly across Africa.

A study published today in PloS Medicine, and led by Dr. Cally Roper of the London School of Hygiene & Tropical Medicine, used genetic methods to characterise how resistance to sulfadoxine has spread across Africa, with a view to determining its geographical origins in order to help improve measures aimed at controlling the spread of drug-resistant P. falciparum.

The team analysed blood samples collected from patients with malaria in various African countries, and searched the scientific literature for other similar studies. They discovered five major variant genetic sequences (three of which contain mutations that confer various degrees of resistance to sulfadoxine in laboratory tests) to be present in Africa, each with a unique geographical distribution. In particular, the data showed that malaria parasites in east and west Africa carry different resistance mutations.

The findings show that sulfadoxine-resistant parasites have emerged independently at multiple sites in Africa, and that the molecular basis for sulfadoxine resistance is different in east and west Africa. This latter result may have clinical implications because it suggests that the effectiveness of sulfadoxine as an antimalarial drug may vary across the continent. They also suggest that economic and transport infrastructures may have played a role in governing recent parasite dispersal across the continent through their influence on the volume of human migration.

Dr. Roper comments: 'Our findings suggest that the effectiveness of sulfadoxine as an antimalarial drug may vary across Africa. They also point to the need to co-ordinate malaria control campaigns across socioeconomically linked areas in Africa, rather than focusing solely on national territories, in order to more effectively reduce the malaria burden in the continent'


'/>"/>

Contact: Gemma Howe
gemma.howe@lshtm.ac.uk
44-782-861-7901
London School of Hygiene & Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment and retention ... and scientific initiatives have all marked the last 12 months at Roswell Park ... of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined the many ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... Ontario (PRWEB) , ... February 05, 2016 , ... After ... Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned to ... Scarborough Hospital. He successfully completed his first three-year term as chief and began a ...
(Date:2/5/2016)... ... 05, 2016 , ... US Sports Camps , official operators of Nike ... high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in the picturesque New ... ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are thrilled to be ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... management solutions to healthcare systems, today announced results for ... --> --> GAAP ... $130.3 million, up $5.1 million or 4.1% from the ... 7.2% from the fourth quarter of 2014. Revenue for ...
(Date:2/4/2016)... SILVER SPRING, Md. , Feb. 4, 2016 ... Robert Califf , the FDA,s Deputy Commissioner for Medical Products ... far-reaching action plan to reassess the agency,s approach to opioid ... the epidemic, while still providing patients in pain access to ... The FDA will: , Re-examine the risk-benefit ...
(Date:2/4/2016)... India , February 4, 2016 ... the new Market Research Report "North American Automated External ... Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, Homecare ... American automated external defibrillators (AED) report defines and segments ... the revenue. This market is estimated to grow to ...
Breaking Medicine Technology: